시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 유전성 유방암 및 난소암 증후군 치료 시장 보고서(2025년)
Hereditary Breast and Ovarian Cancer Syndrome Treatment Global Market Report 2025
상품코드 : 1691860
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,496,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,390,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,284,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 유전성 유방암 및 난소암 증후군 치료 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 예측기간의 성장은 인공지능의 역활 확대, 유전 카운셀링의 접근성 확대, 표적요법의 규제승인, 개별화 치료계획, 연구에 있어서의 국제공동연구 등에 기인한다고 생각됩니다.

예상되는 유전성 질환 증가는 향후 몇 년간의 유전성 유방암 및 난소암 증후군 치료 시장의 성장을 견인할 것으로 보입니다. 신생아 스크리닝은 출생후 유아의 특정 건강상태를 검사하는 것으로, 의료 전문가가 잠재적인 건강 문제가 발생하기 전에 특정 요구 사항을 확인하고 해결할 수 있습니다. 2022년, 텍사스주 보건국은 신생아 스크리닝 검체의 수리수가 4.3% 증가하여 2021년 729,347 검체에서 2022년에는 761,000 검체로 증가했다고 보고했습니다. 이 중 39만 4,000명의 유아가 스크리닝을 받고, 2022년에는 1,130명이 NBS 질환 중 하나에 걸렸습니다. 그러므로, 유전성 질환의 급증은 유전성 유방암 및 난소암 증후군 치료 시장의 성장을 가속하는 중요한 요인입니다.

난소암의 유병률 상승은 유전성 유방암 및 난소암 증후군 치료 시장의 성장을 더욱 촉진할 것으로 예상됩니다.난소의 악성종양인 난소암은 장수화, 출산 지연, 라이프스타일 변화 등의 요인으로 유병률이 증가하고 있습니다. 세계 난소암 연합의 2022년 2월의 보고서에 의하면, 난소암은 2020년에 세계에서 313,959명의 여성이 앓고 있으며, 이 수는 2020년부터 2040까지 연간 42% 증가하여 445,721명이 될 것으로 예측되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

JHS
영문 목차

영문목차

Treatment for hereditary breast and ovarian cancer syndrome (HBO) refers to a comprehensive set of measures and medical strategies aimed at addressing the heightened risk of developing breast and ovarian cancers in individuals with a genetic predisposition to the syndrome. The objective of hereditary breast and ovarian cancer syndrome (HBO) treatment is to either prevent the onset of cancer or detect it at an early, more treatable stage.

The primary treatments for hereditary breast and ovarian cancer syndrome include hormonal therapy, chemoprevention, genetic counseling, medication, and other therapeutic approaches. Hormone replacement therapy, specifically estrogen-based and of a temporary nature, is targeted at alleviating individual acute symptoms in cases of hereditary breast and ovarian cancer (HBOC) syndrome, particularly in individuals with BRCA1 or BRCA2 mutations. Diagnosis involves genetic testing, magnetic resonance imaging (MRI), mammography, and other methods. Medications can be administered through various routes, including oral, parenteral, and others, with delivery facilitated by hospitals, specialty clinics, home care services, and other healthcare providers.

The hereditary breast and ovarian cancer syndrome market research report is one of a series of new reports from The Business Research Company that provides hereditary breast and ovarian cancer syndrome market statistics, including hereditary breast and ovarian cancer syndrome industry global market size, regional shares, competitors with a hereditary breast and ovarian cancer syndrome market share, detailed hereditary breast and ovarian cancer syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary breast and ovarian cancer syndrome industry. This hereditary breast and ovarian cancer syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hereditary breast and ovarian cancer syndrome treatment market size has grown strongly in recent years. It will grow from $6.72 billion in 2024 to $7.17 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increased awareness and screening, supportive government policies, patient advocacy and empowerment, collaboration in research.

The hereditary breast and ovarian cancer syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $9.19 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to the growing role of artificial intelligence, expanded access to genetic counseling, regulatory approvals for targeted therapies, personalized treatment plans, international collaborations in research. Major trends in the forecast period include gene editing technologies, advancements in immunotherapy, technological advances in oncology, immunotherapy for BRCA-related cancers, comprehensive multidisciplinary care.

The anticipated increase in genetic disorders is set to drive the growth of the hereditary breast and ovarian cancer syndrome treatment market in the coming years. Newborn screening, a post-birth examination for specific health conditions in infants, enables health professionals to identify and address specific needs before any potential health issues arise. This screening could identify infants at a higher risk of developing breast and ovarian cancer, allowing for early preventive measures. In 2022, the Texas Department of State Health Services reported a 4.3% increase in newborn screening specimens received, rising from 729,347 in 2021 to 761,000 in 2022. Of these, approximately 394,000 babies were screened, with 1,130 affected by one of the NBS disorders in 2022. Therefore, the surge in genetic disorders is a key factor propelling the growth of the hereditary breast and ovarian cancer syndrome treatment market.

The rising prevalence of ovarian cancer is expected to further fuel the growth of the hereditary breast and ovarian cancer syndrome treatment market. Ovarian cancer, a malignant tumor in the ovaries, has seen increased prevalence due to factors such as increased longevity, delayed childbearing, and changes in lifestyle. Hereditary Breast and Ovarian Cancer Syndrome (HBOC), a genetic condition elevating the risk of breast, ovarian, and other cancers, is a significant contributor to this trend. According to the World Ovarian Cancer Coalition's February 2022 report, ovarian cancer affected 313,959 women globally in 2020, and this number is projected to rise by 42% to 445,721 between 2020 and 2040. Consequently, the growing prevalence of ovarian cancer is a driving force behind the growth of the hereditary breast and ovarian cancer syndrome treatment market.

Major companies in the hereditary breast and ovarian cancer syndrome treatment market are adopting innovative treatment options, such as comprehensive risk tests, to enhance their services. A comprehensive risk assessment test is a tool designed to identify an individual's risk of developing a disorder or experiencing symptoms of a disease. Genetic Technologies Limited, an Australia-based molecular diagnostics company, launched a groundbreaking comprehensive risk assessment test in February 2023. This test combines gene mutation testing for breast and ovarian cancers, assesses hereditary and non-hereditary risk factors, and calculates the GeneType risk score for both cancers. It targets women over 30 at a higher risk of breast and ovarian cancer in the general population.

In March 2023, Invitae Corporation, a US-based biotechnology company, entered into a partnership with Epic Systems Corporation to streamline the genetic testing process. This collaboration aims to integrate genetic information into standard workflows, facilitating enhanced personalized healthcare delivery within the Epic community. Epic Systems Corporation, a US-based platform provider, plays a crucial role in evaluating a patient's risk for hereditary cancer, including hereditary breast and ovarian cancer syndrome (HBOC).

Major companies operating in the hereditary breast and ovarian cancer syndrome treatment market report are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co., AbbVie Inc., Bayer AG, Sanofi-Aventis LLC, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Vertex Pharmaceuticals Inc., Mercy Health, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Limited, Seagen Inc., LEO Pharma Inc., LifeLabs Genetics, Natera Inc., Fresenius Kabi AG, Myriad Genetics Inc., Invitae Corporation, Editas Medicine Inc., GenMark Diagnostics Inc., Genentech Inc., CRISPR Therapeutics AG, Advocate Health Care

North America was the largest region in the hereditary breast and ovarian cancer syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary breast and ovarian cancer syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hereditary breast and ovarian cancer syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hereditary breast and ovarian cancer syndrome treatment market consists of revenues earned by entities by providing services such as genetic testing and counseling, surveillance, screening, prophylactic surgeries, chemoprevention, clinical trials, ongoing monitoring, family testing, and psychosocial support. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary breast and ovarian cancer syndrome treatment market also includes sales of lynparza, talazoparib, rucaparib, and niraparib. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hereditary Breast and Ovarian Cancer Syndrome Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hereditary breast and ovarian cancer syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for hereditary breast and ovarian cancer syndrome treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hereditary breast and ovarian cancer syndrome treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Characteristics

3. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Trends And Strategies

4. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Growth Analysis And Strategic Analysis Framework

6. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Segmentation

7. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Regional And Country Analysis

8. Asia-Pacific Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

9. China Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

10. India Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

11. Japan Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

12. Australia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

13. Indonesia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

14. South Korea Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

15. Western Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

16. UK Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

17. Germany Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

18. France Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

19. Italy Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

20. Spain Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

21. Eastern Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

22. Russia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

23. North America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

24. USA Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

25. Canada Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

26. South America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

27. Brazil Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

28. Middle East Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

29. Africa Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

30. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Competitive Landscape And Company Profiles

31. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Other Major And Innovative Companies

32. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

34. Recent Developments In The Hereditary Breast and Ovarian Cancer Syndrome Treatment Market

35. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기